Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul-Sep;34(3):180-184.
doi: 10.4103/iju.IJU_378_17.

STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs

Aditya Prakash Sharma  1 , Ravimohan S Mavuduru  1 , Girdhar Singh Bora  1 , Sudheer K Devana  1 , Shrawan K Singh  1 , Arup K Mandal  1
Affiliations
Review

STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs

Aditya Prakash Sharma et al. Indian J Urol. 2018 Jul-Sep.

Abstract

With the emergence of recent landmark trials, the treatment for hormone-sensitive metastatic prostate cancer (hsMPC) is changing from androgen deprivation therapy (ADT) alone to combination therapy. Both, docetaxel chemotherapy and abiraterone in addition to ADT have been extensively studied in well-conducted randomized controlled trials and were shown to improve outcomes. However, this paradigm shift in the treatment has also raised some queries. This mini review reflects upon the four landmark trials and tries to provide some perspective about the decision-making process for the patients with hsMPC.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: There are no conflicts of interest.

Figures

Figure 1
Figure 1
Summary of the trials on combination therapies in metastatic hormone-sensitive prostate cancer. ADT: Androgen deprivation therapy, PFS: Progression-free survival, OS: Overall survival, HR: Hazard ratio, NA: Not available, *CHAARTED distributed patients into high volume and low volume in which high volume of metastases was defined by the presence of visceral metastases or four or more bone lesions with at least one beyond the vertebral bodies and pelvis
See this image and copyright information in PMC

References

    1. Huggins C, Stephens RC, Hodges CV. Studies on prostatic cancer: 2.The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209.
    1. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer. 2010;17:R305–15. - PMC - PubMed
    1. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9(Suppl 1):S3–8. - PMC - PubMed
    1. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–46. - PMC - PubMed
    1. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77. - PMC - PubMed